Obesity is a significant public health concern and a growing epidemic in the G7 countries. The body of evidence highlighting the physical and economic impact of obesity on society is steadily increasing. Despite the disease’s prevalence, few drug treatments are available, especially in Europe and Japan. Available treatments have either undesirable risk:benefit profiles or severe payer restrictions. Consequently, there is a huge market opportunity for an antiobesity drug that elicits sustained weight loss and is safe, well tolerated, and affordable. There is a relatively sparse late-phase pipeline for obesity and a promising volume of activity in early phases of development. However, given the prevalence of obesity, even if effective agents reach the market, stringent payer-controlled usage restrictions are likely to be necessary to limit the impact on healthcare budgets.
- Which metabolic and central pathways have high potential as drug targets?
- What is the prevalence of obesity in the major pharmaceutical markets under study?
- How is obesity currently treated? What do experts think about Novo Nordisk’s Saxenda as a treatment for obese / overweight patients?
- What is the current level of unmet need according to obesity experts? How will this need be addressed over the 2018-2028 forecast period?
- What is the commercial potential of Novo Nordisk’s semaglutide and Eli Lilly’s tirzepatide? How do leaders in the field of obesity management rate these drug candidates?
- How will the obesity market evolve over the next ten years?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.